Glycosmedia Weekly Diabetes News - 04/01/2022

Type 1 diabetes in adults: diagnosis and management

NICE guideline [NG17]Published: 26 August 2015 Last updated: 31 March 2022 (NICE)

Type 2 diabetes in adults: management

NICE guideline [NG28]Published: 02 December 2015 Last updated: 31 March 2022 (NICE)

Diabetes (type 1 and type 2) in children and young people: diagnosis and management

NICE guideline [NG18]Published: 01 August 2015 Last updated: 31 March 2022 (NICE)

Launch of the ABCD audit for the Omnipod insulin pump

ABCD is pleased to announce the launch of the ABCD International Omnipod audit and would like to invite you to take part (ABCD)

Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases

This systematic review and meta-analysis of RCTs found that use of GLP-1 RAs was associated with increased risk of gallbladder or biliary diseases, especially when used at higher doses, for longer durations, and for weight loss (JAMA Internal Medicine)

Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently

Increasing evidence suggests that sodium–glucose cotransporter 2 inhibitors (SGLT2is) have beneficial effects across all stages of the cardiorenal metabolic continuum, reducing morbidity and mortality in a wide range of individuals, from those with diabetes and multiple risk factors to those with established heart failure and chronic kidney disease, regardless of the presence of diabetes (Diabetes Therapy)

Coming Full Circle: Prioritizing Early Glycemic Control to Reduce Microvascular and Macrovascular Complications in People With Type 2 Diabetes

Analysis from the Dapagliflozin Effect on Cardiovascular Events trial (DECLARE-TIMI 58) on the association of baseline HbA1c with cardiovascular and kidney outcomes (Diabetes Care)

Glycemic outcomes of Advanced Hybrid Closed Loop system in children and adolescents with Type 1 Diabetes, previously treated with Multiple Daily Injections (MiniMed 780G system in T1D individuals, previously treated with MDI)

Children and adolescents with T1D on MDI therapy who initiated the AHCL system following a 10-days structured protocol achieved the internationally recommended goals of glycemic control with TIR > 70% and a HbA1c of < 7% (BMC Endocrine Disorders)

Achieving diabetes treatment targets in people with registered mental illness is similar or improved compared to those without: analyses of linked observational datasets

People with registered mental illness appear comparable or better able to achieve diabetes treatment targets than those without. Achieving HbA1c targets is influenced by social disadvantage (Diabetic Medicine)

Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications

Dapagliflozin contributes to the control of CV risk factors and reduces the risk of microvascular complications (nephropathy and retinopathy) and other non-classical complications of T2DM. The underuse of SGLT2i in general and dapagliflozin in particular, even in patients whose profiles suggest that they could greatly benefit from SGLT2i treatment, indicates that greater effort is needed to translate scientific evidence into actual clinical practice to improve patients’ quality of life (Diabetes Therapy )

Renoprotective effect of additional sodium-glucose cotransporter 2 inhibitor therapy in type 2 diabetes patients with rapid decline and preserved renal function

Early intervention with SGLT2i may have renoprotective effects in T2D patients with rapid decline and preserved renal function (Journal of Diabetes Investigation)